Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
, 15 (13), 1613-9

Pentoxifylline Versus Prednisolone for Severe Alcoholic Hepatitis: A Randomized Controlled Trial

Affiliations
Randomized Controlled Trial

Pentoxifylline Versus Prednisolone for Severe Alcoholic Hepatitis: A Randomized Controlled Trial

Binay Krishna De et al. World J Gastroenterol.

Abstract

Aim: To compare the efficacy of pentoxifylline and prednisolone in the treatment of severe alcoholic hepatitis, and to evaluate the role of different liver function scores in predicting prognosis.

Methods: Sixty-eight patients with severe alcoholic hepatitis (Maddrey score > or = 32) received pentoxifylline (n = 34, group I) or prednisolone (n = 34, group II) for 28 d in a randomized double-blind controlled study, and subsequently in an open study (with a tapering dose of prednisolone) for a total of 3 mo, and were followed up over a period of 12 mo.

Results: Twelve patients in group II died at the end of 3 mo in contrast to five patients in group I. The probability of dying at the end of 3 mo was higher in group II as compared to group I (35.29% vs 14.71%, P = 0.04; log rank test). Six patients in group II developed hepatorenal syndrome as compared to none in group I. Pentoxifylline was associated with a significantly lower model for end-stage liver disease (MELD) score at the end of 28 d of therapy (15.53 +/- 3.63 vs 17.78 +/- 4.56, P = 0.04). Higher baseline Maddrey score was associated with increased mortality.

Conclusion: Reduced mortality, improved risk-benefit profile and renoprotective effects of pentoxifylline compared with prednisolone suggest that pentoxifylline is superior to prednisolone for treatment of severe alcoholic hepatitis.

Figures

Figure 1
Figure 1
Survival curves (Kaplan-Meier life table analysis) of patients receiving pentoxifylline (group I) as compared to patients receiving prednisolone (group II), at the end of 3 mo of therapy.
Figure 2
Figure 2
Summary of trial design and follow-up.

Comment in

Similar articles

See all similar articles

Cited by 53 PubMed Central articles

See all "Cited by" articles

Publication types

Feedback